In 2019, it was estimated that there were around 10 deaths due to whooping cough (pertussis) in the United States. This statistic shows the number of deaths caused by whooping cough in the U.S. from 1990 to 2019.

The number of cases of pertussis worldwide increased compared to the previous couple of years, but remained significantly lower compared to the number of reported cases in 1980. This statistic shows the number of cases of pertussis reported each year from 1980 to 2023 worldwide, by region.

The states with the highest rates of pertussis include Vermont, Wisconsin, Alaska and Maine. Pertussis is more commonly known as whooping cough. It is a respiratory disease that causes uncontrollable coughing. Whooping cough is highly contagious, but deaths are rare.

Pertussis vaccination

There are two vaccines in the U.S. that help to prevent pertussis. These are the DTaP, for children under 7 years, and the Tdap, for older children, teens and adults. These vaccines are highly recommended, and a majority of children and teens receive them. In 2017, around 83 percent of children aged 19 to 35 months had received the DTaP vaccine.

Pertussis cases

The number of cases of pertussis in the United States have decreased significantly since the introduction of vaccines that prevent the disease. In 1950, there were around 120,700 new cases of pertussis in the U.S., compared to just under 18,000 new cases in 2016. In that year, there were around 5.56 new cases of pertussis per 100,000 population.

Pertussis Vaccination Market Outlook

The global pertussis vaccination market size was valued at approximately USD 3.2 billion in 2023 and is expected to reach USD 5.6 billion by 2032, growing at a compound annual growth rate (CAGR) of 6.1%. This growth is primarily driven by increasing awareness about the importance of vaccination, rising incidences of pertussis, and government initiatives to include pertussis vaccines in national immunization programs. The global rise in healthcare expenditure and the development of new and improved vaccines further contribute to the market's expansion.

One of the significant growth factors for the pertussis vaccination market is the increasing incidence of pertussis or whooping cough globally. Pertussis is highly contagious and can be particularly severe in infants and young children, leading to hospitalizations and, in some cases, death. This has heightened the urgency among healthcare providers and governments to ensure widespread vaccination coverage. Public health campaigns and educational programs emphasizing the importance of timely vaccination are gaining momentum, thereby boosting the market demand.

Technological advancements in vaccine production are another pivotal growth driver. Modern biotechnology has enabled the development of acellular vaccines, which are associated with fewer side effects compared to whole-cell vaccines. These vaccines are increasingly being adopted in immunization programs worldwide. Moreover, ongoing research and development activities aimed at improving vaccine efficacy and delivery mechanisms play a crucial role in propelling the market forward. The emergence of combination vaccines, which protect against multiple diseases with a single injection, also contributes to market growth by simplifying immunization schedules and improving compliance.

Government initiatives and funding are substantial catalysts for market growth. Many countries have incorporated pertussis vaccination into their national immunization schedules, often providing these vaccines for free or at subsidized rates. International organizations, such as the World Health Organization (WHO) and the Global Alliance for Vaccines and Immunization (GAVI), support these efforts by providing technical and financial assistance. This global push for higher vaccination rates is expected to sustain market growth over the forecast period.

The Diphtheria, Tetanus, and Pertussis Combined Vaccine plays a crucial role in the global fight against pertussis, offering protection not only against whooping cough but also against diphtheria and tetanus. This combination vaccine simplifies immunization schedules, making it easier for healthcare providers to ensure comprehensive protection for children and adults alike. The integration of these vaccines into a single shot has been a significant advancement in public health, reducing the number of injections required and improving compliance rates. As governments and health organizations continue to promote the importance of vaccination, the combined vaccine is increasingly being adopted in national immunization programs worldwide. Its effectiveness in preventing multiple diseases with a single dose underscores its importance in achieving higher vaccination coverage and enhancing public health outcomes.

The regional outlook for the pertussis vaccination market shows significant growth potential in regions such as Asia Pacific and Latin America, driven by the increasing birth rates and growing healthcare infrastructure. North America and Europe are expected to maintain steady growth due to existing high vaccination coverage and ongoing public health initiatives. In contrast, the Middle East & Africa may witness slower growth due to economic constraints and lower healthcare access, but ongoing international support efforts aim to improve vaccination rates in these regions.

Vaccine Type Analysis

The vaccine type segment in the pertussis vaccination market is categorized into whole-cell vaccines and acellular vaccines. Whole-cell vaccines have been in use for several decades and were among the first vaccines developed to combat pertussis. Despite their efficacy, these vaccines are often associated with higher rates of adverse reactions, which has led to a gradual decline in their usage over the years. However, they

In 2019, there were 5.67 new cases of pertussis per 100,000 population. This statistic shows the number of new cases of pertussis - also known as whooping cough - per 100,000 population in the U.S. from 1950 to 2019.

The Global Diphtheria Vaccine Sales Market size is expected to grow from $1.6 billion in 2018 to $XX billion by 2028, representing a compound annual growth rate (CAGR) of 5.3%. The growth in this market can be attributed to factors such as growing awareness about the disease and vaccination programs for infants and children, increasing concern over the inadequacy of current vaccines against certain strains of diphtheria, and increased government support for research on new vaccines against diphtheria in countries.

Diphtheria Vaccine Sales:

Diphtheria is a highly contagious bacterial disease that can cause severe respiratory problems, heart failure, and death. The diphtheria vaccine is used to prevent this disease. There are different types of diphtheria vaccine available, such as DTaP (diphtheria, Tetanus, and pertussis), DT (diphtheria and tetanus), Tdap (tetanus, diphtheria, and pertussis) for adults. Diphtheria is a bacterial infection that can cause serious problems, such as difficulty breathing and heart failure. The diphtheria vaccine is used to help protect against this disease. There are different types of the vaccine, depending on when it is given: DTaP for infants and children younger than seven years of age, DT for children seven years of age and older, Tdap for adolescents and adults.

On the basis of Types, the market is segmented into DTaP, DT, Td, Tdap.

DTaP:

DTaP is a Combination Vaccine that combines protection against three diseases: diphtheria, tetanus, and pertussis (whooping cough). DTaP protects children from these serious diseases caused by bacteria. Diphtheria and whooping cough are spread from person to person through coughing or sneezing. Tetanus enters the body through cuts or wounds. DTaP is a vaccine that helps protect infants and children younger than seven years of age from three diseases: diphtheria, tetanus, and pertussis. DTaP is usually given as a series of five shots.

DT:

DT is diphtheria and tetanus vaccine that is given as a shot. DT helps protect children seven years of age and older, adolescents, and adults from two diseases: diphtheria and tetanus. Diphtheria is a bacterial infection that can cause serious problems, such as difficulty breathing and heart failure. DT is a vaccine that protects against diphtheria and tetanus (lockjaw). The diphtheria part of DTaP helps children younger than seven years of age develop immunity to the bacteria that cause this disease. Tetanus enters the body through cuts or wounds.

Td:

Td is tetanus and diphtheria vaccine. Td protects adolescents and adults from two diseases: tetanus and diphtheria. Td is a booster shot that helps protect adolescents and adults from two diseases: diphtheria and tetanus. Diphtheria is a bacterial infection that can cause serious problems, such as difficulty breathing and heart failure. Tetanus enters the body through cuts or wounds. Td is usually given every ten years as a booster shot to help protect adolescents and adults from two diseases: diphtheria and tetanus.

On the basis of Application, the market is segmented into For infants and children younger than seven years of age, For adolescents and adults.

For infants and children younger than seven years of age:

The diphtheria vaccine is used to prevent this disease in infants and children. The diphtheria vaccine is given to infants and children younger than seven years of age. It helps protect them from getting the bacterial infection that causes diphtheria. Also, DTaP is required for school entry in some states, so it's important your child gets all doses on schedule. The vaccination schedule begins with a series of two shots at two and four months of age, followed by a booster shot at six years of age.

For adolescents and adults:

The diphtheria vaccine is also used to protect adolescents and adults from getting the bacterial infection that causes diphtheria. The vaccination schedule for adolescents and adults begins with a series of two shots, followed by a booster shot every ten years. Protection against diphtheria can last up to 20 years. The diphtheria vaccine is used to prevent this disease in infants and children, adolescents, and adults.

On the basis of Region, the market is segmented into North America, Latin America, Europe, Asia Pacific, and the Middle East & Africa. North America is expected to hold the largest market share in 2028. Latin America is expected to be the fastest-growing market during the forecast period. Europe is expected to be the second-largest market for Diphtheria Vaccines dur

Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Outlook

The global Diphtheria, Tetanus, and Pertussis (DTaP) vaccine market size is poised to witness significant growth from 2024 to 2032, with an estimated market value of $4.9 billion in 2023 and a forecasted value of approximately $8.3 billion by 2032, growing at a compounded annual growth rate (CAGR) of 6.2%. This impressive growth trajectory is primarily driven by the continuous advancements in vaccine technology, increasing awareness about vaccine-preventable diseases, and the robust initiatives undertaken by both governmental and non-governmental organizations to increase immunization coverage worldwide. The ongoing development of healthcare infrastructure, particularly in emerging economies, further contributes to the promising outlook for the DTaP vaccine market.

A key growth factor for the DTaP vaccine market is the rising incidence of pertussis and other related infections, which has heightened the demand for effective immunization programs. In recent years, outbreaks of pertussis have been reported in both developed and developing regions, underscoring the need for comprehensive vaccination strategies. This scenario has led to increased governmental and public health efforts to ensure widespread vaccine accessibility and coverage, thereby bolstering market growth. Moreover, the increasing recognition of the importance of booster doses in maintaining immunity levels across different age groups has further fueled the market demand for DTaP vaccines.

Another significant driver of market growth is the technological advancements in vaccine production, which have resulted in safer and more efficacious vaccines. The development of acellular vaccines, which are associated with fewer side effects compared to whole-cell vaccines, has been a pivotal factor in increasing vaccine acceptance and compliance. Furthermore, ongoing research and development activities are focused on enhancing vaccine formulations and delivery mechanisms, ensuring the continued relevance and effectiveness of the DTaP vaccines. These innovations are attracting significant investments from both public and private sectors, thereby further securing the market's growth trajectory over the forecast period.

The supportive policies and funding from international organizations and governments also play a crucial role in propelling the growth of the DTaP vaccine market. Various initiatives, such as the World Health Organization's Expanded Programme on Immunization and national vaccination programs, have been instrumental in enhancing the reach and uptake of DTaP vaccines. Additionally, collaborations between vaccine manufacturers and public health agencies aimed at improving vaccine production and distribution capabilities are expected to further stimulate market expansion. Together, these factors create an ecosystem that is conducive to sustained growth in the global DTaP vaccine market.

The Tetanus Vaccine, a crucial component of the DTaP combination, plays a significant role in preventing tetanus, a potentially fatal disease caused by the bacterium Clostridium tetani. This vaccine is essential not only for children but also for adults, particularly those in high-risk occupations or environments where injuries are common. The importance of the Tetanus Vaccine is underscored by its inclusion in routine immunization schedules worldwide, ensuring that populations are protected against this serious infection. As part of the broader DTaP vaccine, the Tetanus Vaccine contributes to the overall effectiveness of immunization programs aimed at reducing the incidence of vaccine-preventable diseases. Its role in maintaining public health is further emphasized by the ongoing efforts to improve vaccine formulations and accessibility, ensuring that individuals across different regions have access to this life-saving intervention.

Regionally, North America and Europe have been at the forefront of the DTaP vaccine market due to well-established healthcare infrastructure and high awareness levels about immunization. However, the Asia Pacific region is projected to exhibit the highest growth rate, driven by substantial improvements in healthcare access and increasing governmental focus on immunization programs. The region's large population base, coupled with rising healthcare expenditure and advancements in vaccine distribution networks, contribute to this optimistic regional outlook. As countries in Asia Pacific continue to prioritize vaccination as part of their public health agendas, the region is expec

Snapshot img { margin: 10px !important; }

Overview of the drug development for pertussis

Pertussis is a highly contagious respiratory disease and is also known as whooping cough. The Bordetella pertussis bacterium is the causing agent of pertussis. When infected by pertussis, patients suffer from uncontrollable, violent coughing, which often makes it difficult to breathe. After coughing, someone with pertussis often needs to take deep breaths, which results in a whooping sound. People of all ages can be affected by pertussis, but it can be very serious, even deadly, for infants aged less than 1 year. People with pertussis usually spread the disease to another person by coughing or sneezing, or when spending a lot of time near one another where they share the breathing space. Many babies with pertussis are infected by older siblings, parents, or caregivers, who are unaware that they have this disease. According to the CDC, in 2015, the World Health Organization reported 142,512 pertussis cases globally and estimated that there were 89,000 deaths. Since 1980s, there has been an increase in the number of reported cases of pertussis in the US. In 2010, the CDC saw an increase in the number of reported cases among 7 to 10 years old. The CDC also observed an increase in the number of cases among teenagers. As a result, the rising incidences of the disease are further expected to boost the drug development for pertussis during the next few years.

According to this pipeline analysis report, most of the drug molecules in the pipeline are being developed for pertussis. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.

Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of pertussis. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are –

• Bharat Biotech
• BIRMEX
• BlueWillow Biologics
• Cadila Healthcare
• LG Chem

Therapeutic assessment of the drug development for pertussis by route of administration

• Intramuscular
• Intranasal
• Subcutaneous
• Epicutaneous
• Intravenous

The intramuscular route of administration (ROA) involves the application of the drug directly into the drug, which will have a more direct effect on the target cells.

Therapeutic assessment of the drug development for pertussis by therapy

• Combination therapy
• Monotherapy

According to this pipeline analysis report, most of the molecules that are currently in the drug development for pertussis are being developed as combination therapy drugs and most of these molecules are in the pre-clinical stage of development.

Key questions answered in the report include

• <span style="ba

Pertussis, or whooping cough, is a highly contagious respiratory illness caused by Bordetella pertussis. It primarily affects humans by adhering to the cilia of the upper respiratory tract, releasing toxins that impair ciliary function, and inducing inflammation. It is transmitted through respiratory droplets, and the disease is particularly severe in infants under 1 year of age, often resulting in high morbidity and frequent admission to intensive care units. Globally, the incidence of pertussis has been increasing, with notable increases observed in countries such as the United States, Brazil, and Mexico. In Brazil, the number of reported cases increased sharply in 2024 to 7,438—with a 34.4-fold increase compared to 2023 (N = 216)—with 30 associated deaths, the first since 2021. While most cases still affect children under 14 years of age, infections among individuals over 15 years of age have also increased, suggesting a demographic shift. The number of hospitalizations increased from 236 in 2023 to 739 in 2024 (a 3.1-fold increase). Geographically, the South region recorded the highest number of cases (N = 3,579), followed by the Southeast (N = 3,134). Incidence rates mirrored this pattern, with the South reporting 11.5 cases per 100,000 inhabitants and the Southeast, 3.54 per 100,000 inhabitants. Despite a slight improvement in vaccination coverage, it remains below the World Health Organization’s recommended threshold of 90%. Vaccination—particularly with the pentavalent and diphtheria, tetanus, and acellular pertussis (DTaP) vaccines—remains a critical tool for outbreak prevention; however, waning immunity underscores the need for booster doses across age groups. The coronavirus disease 2019 (COVID-19) pandemic likely reduced transmission temporarily due to mitigation measures and also led to missed routine vaccinations. To address this resurgence, Brazil must prioritize increasing vaccination coverage, especially among children, strengthening epidemiological surveillance, and improving healthcare provider training in immunization practices.

ObjectivesIn February 2012, the Advisory Committee on Immunization Practices (ACIP) advised that all adults aged ≥65 years receive a single dose of reduced-antigen-content tetanus, diphtheria, and acellular pertussis (Tdap), expanding on a 2010 recommendation for adults >65 that was limited to those with close contact with infants. We evaluated clinical and economic outcomes of adding Tdap booster of adults aged ≥65 to “baseline” practice [full-strength DTaP administered from 2 months to 4–6 years, and one dose of Tdap at 11–64 years replacing decennial Td booster], using a dynamic model.MethodsWe constructed a population-level disease transmission model to evaluate the cost-effectiveness of supplementing baseline practice by vaccinating 10% of eligible adults aged ≥65 with Tdap replacing the decennial Td booster. US population effects, including indirect benefits accrued by unvaccinated persons, were estimated during a 1-year period after disease incidence reached a new steady state, with consequences of deaths and long-term pertussis sequelae projected over remaining lifetimes. Model outputs include: cases by severity, encephalopathy, deaths, costs (of vaccination and pertussis care) and quality-adjusted life-years (QALYs) associated with each strategy. Results in terms of incremental cost/QALY gained are presented from payer and societal perspectives. Sensitivity analyses vary key parameters within plausible ranges.ResultsFor the US population, the intervention is expected to prevent >97,000 cases (>4,000 severe and >5,000 among infants) of pertussis annually at steady state. Additional vaccination costs are $4.7 million. Net cost savings, including vaccination costs, are $47.7 million (societal perspective) and $44.8 million (payer perspective). From both perspectives, the intervention strategy is dominant (less costly, and more effective by >3,000 QALYs) versus baseline. Results are robust to sensitivity analyses and alternative scenarios.ConclusionsImmunization of eligible adults aged ≥65, consistent with the current ACIP recommendation, is cost saving from both payer and societal perspectives.

The Gram-negative bacterium Bordetella pertussis is the causative agent of whooping cough, a serious respiratory infection causing hundreds of thousands of deaths annually worldwide. There are effective vaccines, but their production requires growing large quantities of B. pertussis. Unfortunately, B. pertussis has relatively slow growth in culture, with low biomass yields and variable growth characteristics. B. pertussis also requires a relatively expensive growth medium. We present a new, curated flux balance analysis-based model of B. pertussis metabolism. We enhance the model with an experimentally-determined biomass objective function, and we perform extensive manual curation. We test the model’s predictions with a genome-wide screen for essential genes using a transposon-directed insertional sequencing (TraDIS) approach. We test its predictions of growth for different carbon sources in the medium. The model predicts essentiality with an accuracy of 83% and correctly predicts improvements in growth under increased glutamate:fumarate ratios. We provide the model in SBML format, along with gene essentiality predictions.

In 2022, the incidence rate for pertussis per 100,000 population in Japan decreased by *** (-***** percent) since 2021. As a result, the incidence rate in Japan saw its lowest number in 2022 with ***. Find more statistics on other topics about Japan with key insights such as incidence rate for measles per 100,000 population and number of acquired immunodeficiency syndrome (AIDS) per 100,000 inhabitants.

Project Tycho data include counts of infectious disease cases or deaths per time interval. A count is equivalent to a data point. Project Tycho level 1 data include data counts that have been standardized for a specific, published, analysis. Standardization of level 1 data included representing various types of data counts into a common format and excluding data counts that are not required for the intended analysis. In addition, external data such as population data may have been integrated with disease data to derive rates or for other applications.

Version 1.0.0 of level 1 data includes counts at the state level for smallpox, polio, measles, mumps, rubella, hepatitis A, and whooping cough and at the city level for diphtheria. The time period of data varies per disease somewhere between 1916 and 2011. This version includes cases as well as incidence rates per 100,000 population based on historical population estimates. These data have been used by investigators at the University of Pittsburgh to estimate the impact of vaccination programs in the United States, published in the New England Journal of Medicine: http://www.nejm.org/doi/full/10.1056/NEJMms1215400. See this paper for additional methods and detail about the origin of level 1 version 1.0.0 data.

Level 1 version 1.0.0 data is represented in a CSV file with 7 columns:

• epi_week: a six digit number that represents the year and epidemiological week for which disease cases or deaths were reported (yyyyww)
• state: the two digit postal code state abbreviation that represents the state for which a count has been reported
• loc: the name of a state or city for which a count has been reported, capitalized
• loc_type: the type of location (STATE or CITY) for which a count has been reported
• disease: the disease for which a count has been reported: HEPATITIS A, MEASLES, MUMPS, PERTUSSIS, POLIO, RUBELLA, SMALLPOX, or DIPHTHERIA
• cases: the number of cases reported for the specified disease, epidemiological week, and location
• incidence_per_100000: the number of cases per 100,000 people, computed using historical population counts for cities and states as reported by the US Census Bureau

Tetanus Toxoid Vaccine Market Outlook

The global tetanus toxoid vaccine market size is poised for significant growth over the coming years, with projections indicating an impressive compound annual growth rate (CAGR) of 5.4% from 2024 to 2032. In 2023, the market size was valued at approximately USD 2.3 billion and is forecasted to reach around USD 3.7 billion by 2032. This growth is fueled by several key factors, including increasing awareness about the importance of immunization, government initiatives supporting vaccination programs, and the rising prevalence of tetanus cases in certain regions. The demand for both monovalent and combination vaccines is expected to rise as more health systems intensify their efforts to prevent this life-threatening infection.

One of the primary growth drivers in the tetanus toxoid vaccine market is the growing awareness and emphasis on preventive healthcare measures. As healthcare systems worldwide continue to focus on preventing diseases rather than solely treating them, vaccination has become a cornerstone of public health policy. This shift is bolstered by robust governmental and non-governmental support, which includes funding and awareness campaigns aimed at improving vaccination rates. The importance of tetanus toxoid vaccination is highlighted in both developing and developed nations, where efforts are made to reach even the most remote populations, thereby minimizing the incidence of tetanus-related complications and deaths.

Furthermore, technological advancements and innovations in vaccine development have spurred market growth. The development of combination vaccines, which offer protection against multiple diseases in a single shot, has gained significant traction. Such vaccines not only improve patient compliance by reducing the number of injections required but also enhance immunization coverage. The introduction of combination vaccines that include tetanus toxoid, such as those offering diphtheria and pertussis protection, is particularly appealing in pediatric and adult immunization schedules. This innovation is driving market expansion as it aligns with efforts to streamline vaccination protocols and improve healthcare delivery efficiency.

Additionally, a surge in government and private sector partnerships has strengthened the infrastructure supporting vaccine distribution and administration. These collaborations have facilitated the establishment of robust supply chains, ensuring that vaccines are accessible in both urban and rural areas. Public health campaigns and educational initiatives have been pivotal in addressing vaccine hesitancy, a challenge that previously hindered market growth. By tackling misinformation and promoting the benefits of vaccination, stakeholders have been able to increase acceptance rates, thereby expanding the market for tetanus toxoid vaccines.

Regionally, the tetanus toxoid vaccine market exhibits varying growth patterns, with significant opportunities in Asia Pacific and Africa due to high prevalence rates and ongoing immunization initiatives. In North America and Europe, mature healthcare systems continue to emphasize booster doses and combination vaccines, sustaining market demand. Additionally, the Middle East & Africa region is witnessing an increase in immunization programs led by both governments and international organizations, contributing to steady market growth. The regional dynamics highlight the global effort to eradicate tetanus and improve health outcomes, with tailored strategies addressing specific regional challenges.

Vaccine Type Analysis

The tetanus toxoid vaccine market is segmented by vaccine type into monovalent and combination vaccines. Monovalent vaccines, which solely target tetanus, have traditionally been the mainstay of tetanus prevention efforts. These vaccines are particularly critical in emergency and post-exposure settings, where rapid immunization is necessary to prevent the onset of tetanus following injuries. The demand for monovalent vaccines remains robust in regions with high incidences of tetanus, especially in areas with inadequate sanitation and healthcare infrastructure. They continue to play a vital role in immunization strategies in resource-limited settings, where healthcare access can be a challenge.

In contrast, combination vaccines are gaining significant traction in markets worldwide. These vaccines, which incorporate multiple antigens, offer convenience by protecting against several diseases with a single injection. The inclusion of tetanus toxoid in combination vaccines such as DTP (Diphtheria, Tetanus, and Pertussis) has furt

Although there has been an overall decline in a number of vaccine-preventable diseases in the U.S., the number of pertussis cases has increased since 1980. This statistic shows the number of reported cases of select vaccine-preventable diseases in the U.S. from 1980 to 2022.

In 2022, there were around 28 cases of tetanus in the United States. The annual number of tetanus cases in the United States has decreased steadily over the past few decades, and in the years 2018 and 2019 there were no reported cases. The decrease in tetanus cases in the United States and around the world is mostly due to high rates of vaccination.

What is tetanus? Tetanus is an infection caused by bacteria that live in the environment. Spores of tetanus bacteria are often found in soil and dust and enter the body through broken skin, such as puncture wounds. Tetanus cannot be spread from one person to another. One of the most common symptoms of tetanus is a tightening of the jaw muscles, leading tetanus to often be called "lockjaw". Other symptoms include muscle spasms, muscle stiffness, trouble swallowing, seizures, headache, and fever. Like in the United States, cases of tetanus have decreased since the year 1980 for every region around the world. In 2022, there were a total of 6,651 cases of tetanus worldwide. The highest number of cases was found in Africa, however the year prior the Eastern Mediterranean reported the most cases.

Tetanus vaccination Vaccination is the best way to protect against tetanus and most cases of tetanus in the United States are among people who have not been vaccinated. There are multiple vaccinations that protect against tetanus as well as other diseases such as DTap, DT, Tdap, and Td. Tetanus vaccinations are safe and effective and recommended for people of all ages, with children receiving multiple vaccinations and adults recommended to get vaccinated every 10 years. As of 2022, around 94 percent of one-year-olds in the United States had received the recommended three doses of the combined diphtheria, tetanus toxoid, and pertussis (DTP3) vaccine.

The share of children aged 12-23 months immunized against diphtheria, pertussis and tetanus (DPT) in the Philippines stood at ** percent in 2023. Between 1980 and 2023, the share of children rose by ** percentage points, though the increase followed an uneven trajectory rather than a consistent upward trend.